Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
This protocol has additional training requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6066 or aboerner@mtcancer.org for additional information.
Tobacco Use Assessment Sub-Study (EAQ16T), Closed to Accrual, effective October 8, 2021.
